L-Carnitine vs Semaglutide
A side-by-side research comparison of L-Carnitine and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | L-Carnitine | Semaglutide |
|---|---|---|
| Full name | L-Carnitine Injectable | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Supplement / Compounded | FDA Approved |
| Mechanism | Transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle, enabling beta-oxidation for ATP production. Also reduces oxidative stress and supports cardiac function. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 161.20 Da | 4,114 Da |
| Half-life | ~2-3 hours (IM) | 7 days (168 hours) |
| Bioavailability | ~100% injectable; ~14-18% oral | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 500-2000 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 2-5x per week | Once weekly |
| Route | Intramuscular or IV injection | Subcutaneous injection |
L-Carnitine reported benefits
- Enhanced fat oxidation
- Improved energy
- Exercise performance
- Cardiac health
- Recovery support
- Mitochondrial function
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.